Goodwin Advised SciNeuro in Entering into a Licensing and Collaboration Agreement with Novartis for $165 Million Upfront and Up to $1.5 Billion in Milestones

Goodwin Advised SciNeuro in Entering into a Licensing and Collaboration Agreement with Novartis for $165 Million Upfront and Up to $1.5 Billion in Milestones

Goodwin advised SciNeuro Pharmaceuticals on entering into a worldwide licensing and collaboration agreement with Novartis Pharma AG to advance SciNeuro’s novel amyloid beta-targeted antibody program for the treatment of Alzheimer’s Disease. The program has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood-brain barrier shuttle technology, offering potential differentiation from existing amyloid beta-targeted agents.

Under the terms of the agreement, SciNeuro will receive an upfront payment of $165 million. In addition, SciNeuro is eligible to receive research funding, and potentially up to $1.5 billion in development, regulatory, and commercial milestones, as well as tiered royalties.

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.

The Goodwin deal team was led by Wenseng 'Wendy' Pan (Partner/ International Trade) and consisted of Christopher Zhong (Associate/ Technology & Life Sciences) and Kevin Guan (Associate/ Life Sciences); Justin Pierce (Partner/ International & Global Trade), Gozde Guckaya (Associate/ International & Global Trade) and Nick Ognibene (Associate/ Global Trade) and Paul Jin (Partner/ Antitrust & Competition), Ortal Ben Aharon (Associate/ Antitrust) and Arom Yun (Associate/ Antitrust).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.